Diamines & Chem. (DIAMINESQ)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Very low debt/equity of 0.06 gives the company room to survive a prolonged downturn.
• Promoter holding of 55.34% aligns long-term interests with minority shareholders.
• Book value of ₹165.96 provides tangible asset support, even though price is above book.
• ROCE of 3.33% is positive despite the net loss, indicating some operating-level capital efficiency.
• Small market cap of ₹236 crore leaves scope for a meaningful recovery if earnings revive.

Concerns

• P/E is 0.00 because the company is loss-making; latest quarter shows sales of ₹8 crore and net loss of ₹3 crore.
• Sales growth of -56.37% and profit growth of -553.33% represent a severe business collapse.
• ROE of -4.45% means shareholder equity is being eroded at the current operating pace.
• Piotroski F-Score of 3/9 indicates poor financial health, and paying 1.64 times book offers no margin of safety.

AI Analysis

Diamines & Chem is the kind of situation that makes value investors uncomfortable. The stock is priced at ₹271.92 and the market capitalisation is ₹236 crore, but the P/E ratio is 0.00 because there are no earnings. Sales have fallen 56.37% and profit growth is minus 553.33%, meaning the business has swung from profit to loss. The latest quarter says it all: revenue of just ₹8 crore and a net loss of ₹3 crore. As Graham would say, an earnings-power valuation is impossible here; I must go to the balance sheet. Book value is ₹165.96 per share, so I would be paying 1.64 times book for a company earning a negative 4.45% on equity. That is not a margin of safety; it is a payment for hope. The balance sheet is not the problem. Debt to equity is only 0.06, so the company is not at risk of insolvency, and ROCE of 3.33% shows some operating capital is still working. But 3.33% is far below an acceptable return. The Piotroski score of 3 out of 9 confirms the financial deterioration. Promoter holding of 55.34% is good for alignment, but good alignment cannot replace missing profits. The 0.42% dividend yield is trivial. Maybe specialty chemicals are at a cyclical low, or maybe the company's competitive position has been permanently damaged. The data do not yet reveal a path to recovery. Buying at ₹271.92 is not a Graham-style bargain; a better price would be well below book value, or I need clear evidence that sales and margins are turning. Until then, I will watch, not buy.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer